Controversies in measuring and valuing indirect costs of productivity foregone in a cost of illness evaluation

Journal of Research in Pharmaceutical Economics

Volumn 8, Issue 3, 1997, Pages 23-30

  Peeples, Patricia J ^a,b   Wertheimer, Albert I ^c   Mackowiak, John I ^d   McGhan, William F ^e  

^a ALZA CORPORATION   (United States)

^b First Health Services Corporation ^*  (United States)

^c First Health Services Corporation   (United States)

^d Center for Outcomes Research   (United States)

^e UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; ARTICLE; EMPLOYMENT; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE POLICY; INJURY; PRIORITY JOURNAL; PRODUCTIVITY; WORK DISABILITY;

EID: 0030930019     PISSN: 08966621     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Eisenberg JM. Why a journal of PharmacoEconomics? PharmacoEconomics 1992;1:2-4.
2. Davies NE, Felder LH. Applying brakes to the runaway American health care system: a proposed agenda. JAMA 1990;263:73-6.
3. Koopmanschap MA, Rutten F. Indirect costs in economic studies: confronting the confusion. PharmacoEconomics 1993;4:446-54.
4. Rice DP. Estimating the cost of illness. Public Health Service. Health Economics Series No. 6. Washington, DC: Government Printing Office, 1966.
5. Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: a replication and update. Health Care Finan Rev 1985;7:61-80.
6. Spilker B, ed. Quality of life assessments in clinical trials. New York: Raven, 1990.
7. Koopmanschap MA, Van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992;34:1005-10.
8. Drummond MF. Cost-of-illness studies: a major headache? PharmacoEconomics 1992;2:1-4.
9. Davey PJ, Leeder SR. The cost of migraine: more than just a headache? PharmacoEconomics 1992;2:5-7.
10. Hodgson TA. The state of the art of cost-of-illness estimates. Adv Health Econ Health Serv Res 1983;4:129-64.
11. Cooper BS, Rice DP. The economic cost of illness revisited. Soc Security Bull 1976;39:21-36.
12. Hodgson TA, Meiners MR. Guidelines for cost of illness studies in the Public Health Service. Prepared for U.S. Public Health Service Task Force on Costs of Illness. Unpublished. 1979.
13. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Health and Society 1982;60:429-63.
14. Hodgson TA. The cost-of-illness studies: no aid to decision making? Comments on the second opinion by Shiell, et al. (Health Policy 1987(8):317-323). Health Policy 1989;11:57-60.
15. Spilker B, Molinek FR Jr, Johnston KA, Simpson RL, Tilson HH. Quality of life bibliography and indexes. Med Care 1990;28(12 Suppl):DS1-77.
16. Schulz RM, Dye J, Joliceur L, et al. Quality of life factors for parents of children with asthma. J Asthma 1994;31:209-19.
17. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992;326:862-6.
18. Paringer L, Berk A. Costs of illness and disease, fiscal year 1975. Report No. 2. Washington DC: Georgetown University Press, 1977.
19. Mishan EJ. Evaluation of life and limb: a theoretical approach. J Political Econ 1971;79:687-705.
20. Warner KE, Luce BR. Cost-benefit and cost-effectiveness analysis in health care: principles, practice and potential. Ann Arbor, MI: Health Administration Press, 1982.
21. Conley BC. The value of human life in the demand for safety. Am Econ Rev 1976;66:45-55.
22. Linnerooth J. The value of human life: a review of the models. Econ Inq 1979;17:52-74.
23. Patrick DL, Erickson P. Health status and health policy: quality of life in health care evaluation and resource allocation. New York: Oxford University Press, 1993.
24. Drummond MF. Principles of economic appraisal in health care. New York: Oxford Medical Publications, 1980.
25. Rice DP, Hodgson TA. Social and economic implications of cancer in the United States. Hyattsville, MD: National Center for Health Statistics, 1981.
26. Thompson MS. Willingness to pay to accept risks to cure chronic disease. Am J Public Health 1986;76:392-6.
27. Detsky AS. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. PharmacoEconomics 1993;3:354-61.
28. Schelling TC. The life you save may be your own. In: Chase SB, ed. Problems in public expenditure analysis. Washington, DC: The Brookings Institution, 1968.
29. Osterhaus JF, Gutterman DL, Plachetka JR. Healthcare resource and lost labor costs of migraine headache in the U.S. PharmacoEconomics 1992;2:67-76.
30. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993;4:353-65.